Janssen presents new realworld evidence at the Annual European Congress of Rheumatology EULAR 2019 which suggests that effective PsA treatment should target more than skin and joints

The Janssen Pharmaceutical Companies of Johnson & Johnson presented new data this week from PsABio its ongoing realworld study of nearly 1000 people with psoriatic arthritis who have started treatment with either Stelara us...